Mot de passe
Afficher le mot de passe
Mot de passe oublié ?
Devenir membre gratuitement
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Cotations dynamiques 


Cours estimé en temps réel. Temps réel estimé Cboe BZX - 28/10 16:27:07
84.915 USD   +4.14%
15:07Les valeurs à suivre aujourd'hui à Wall Street - Jeudi 28 octobre 2021
14:51Merck bat le consensus et relève son objectif annuel
13:42MERCK : resserrement en hausse des objectifs annuels
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteurAnalyses Zonebourse
Actualités dans d'autres langues sur MERCK & CO., INC.
15:52MÄRKTE USA/Wall Street trotzt schwachen BIP-Daten
15:50Merck Raises 2021 Guidance as Drug Demand Firms With Third-Quarter Results Beating Esti..
15:32Thinking about trading options or stock in Apple, Mastercard, Merck, Atlassian, or Baid..
15:16MÄRKTE USA/Schwache BIP-Daten belasten nicht
15:04Health Care Stocks Edge Higher in Premarket Thursday
14:37US-Pharmakonzern Merck hebt Ziele nach unerwartet gutem Quartal an
14:37US-Pharmakonzern Merck hebt Ziele nach unerwartet gutem Quartal an
14:333Q21 Merck Earnings Presentation
14:29Merck tops Q3 forecasts, as health systems adapt to COVID-19
13:28Merck verhoogt outlook
13:10Merck & Co übertrifft im 3Q Erwartungen und erfreut mit Ausblick
13:033Q21 Other Financial Disclosures (Excel)
13:01Merck & Co mit unerwartet gutem Quartal - Ziele angehoben
13:00MERCK : Q3 Earnings Snapshot
13:00Merck & Company Fiscal Q3 2021 Adjusted Earnings, Sales Rise; Updates Fiscal Full-Year ..
12:533Q21 Merck Other Financial Disclosures
12:43Merck Announces Third-Quarter 2021 Financial Results - Form 8-K
12:42MERCK & CO., INC. : Results of Operations and Financial Condition, Financial Statements an..
12:35GUIDANCE : (MRK) MERCK & CO. Expects Fiscal Year 2021 Revenue Range $47.4B - $47.9B
12:35GUIDANCE : (MRK) MERCK & CO. Sees Fiscal Year 2021 EPS Range $5.65 - $5.70
12:34Earnings Flash (MRK) MERCK & CO. Posts Q3 EPS $1.75
12:34Earnings Flash (MRK) MERCK & CO. Reports Q3 Revenue $13.15B
12:31Merck Announces Third-Quarter 2021 Financial Results
09:36¡Vae Victis !
27/10SHAREHOLDER ALERT : WeissLaw LLP Reminds COLB, XLRN, ACBI. and ECHO Shareholders About Its..
27/10Health Care Stocks Slide Wednesday as Biotechs Weigh on Sector
27/10Health Care Stocks Drifting Lower This Afternoon
27/10Merck, Medicines Patent Pool Sign Licensing Agreement To Distribute COVID-19 Pill in Lo..
27/10Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Sa..
27/10Merck & Co. Expands Access to COVID-19 Pill Via Voluntary Licensing Deal
27/10Pharmariese Merck schliesst Deal für Generika von Covid-19-Pille ab
27/10The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir..
27/10The Medicines Patent Poo and Merck Enter into License Agreement for Molnupiravir, an In..
26/10Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen o..
25/10ASTRAZENECA : Daiichi Sankyo in Clinical Trial Collaboration to Evaluate Datopotamab Derux..
25/10Health Care Stocks Higher in Monday Trading Amid Large Gains by Biotechs
25/10XERIS BIOPHARMA : Merck in Collaboration Deal With Option to License ' XeriJect - Shares J..
25/10MERCK : Reports Positive Results From Phase 3 Trials Evaluating Combination HIV-1 Therapy
25/10Health Care Stocks Mixed Premarket Monday
25/10MERCK : European Commission Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemotherapy as..
25/10MERCK : EU Medicines Regulator Starts Rolling Review For Merck And Co.'s COVID-19 Drug
25/10CORONA-BLOG/Merck & Co lässt Molnupiravir in EU fortlaufend prüfen
25/10MERCK : Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investi..
25/10Merck & Co., Inc. Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evalu..
25/10EVAXION BIOTECH A/S : Enters Deal With Merck to Test Cancer Drug Candidate Combination in ..
25/10MERCK : and Ridgeback Announce Initiation of a Rolling Review by the European Medicines Ag..
25/10Merck & Co., Inc. and Ridgeback Biotherapeutics Announces Initiation of A Rolling Revie..
25/10Merck's Phase 3 Trials of HIV-1 Treatment Meet Primary Endpoint
25/10Hummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibo..
25/10MERCK, RIDGEBACK : EMA Begins Rolling Review of Covid-19 Pill
25/10Evaxion Biotech to Study Lead Candidate EVX-01 With Merck's Keytruda
22/10MERCK : Secures European Commission's Approval for Keytruda as Breast Cancer Treatment in ..
22/10MERCK : European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy a..
22/10European Commission Approves Merck?s KEYTRUDA? (pembrolizumab) Plus Chemotherapy as Tre..
22/10Merck Gets European OK for Keytruda in Triple-Negative Breast Cancer
22/10MODERNA : European Medicines Agency's Review for Moderna's COVID-19 Booster Shot Expected ..
21/10MERCK : CDC ACIP Unanimously Votes to Provisionally Recommend Merck's VAXNEUVANCE (Pneumoc..
21/10Mientras PayPal se engancha a Pinterest, Evergrande reaparece
21/10MERCK : Bristol-Myers To Shed Acceleron Stake Ahead Of Merck & Co.'s $11.5 Billion Acquisi..
21/10MERCK : British Government Secures COVID-19 Antivirals from Merck & Co., Pfizer
21/10MERCK : CDC ACIP Unanimously Votes to Provisionally Recommend Merck's VAXNEUVANCE™ (..
21/10CDC ACIP Unanimously Votes to Provisionally Recommend Merck?s VAXNEUVANCE?
20/10U.K. in Agreements for Merck/Ridgeback, Pfizer Covid-19 Antivirals in Development
20/10CORONA-BLOG/Gates-Stiftung kündigt Investition von 120 Mio USD in Covid-Medikamente an
20/10MERCK : to Voluntarily Recall About 22,000 Cubicin Vials Due to Presence of Glass Particle..
20/10MERCK : WHO Program To Acquire Merck & Co.'s COVID-19 Pill Under Aid Program
20/10MERCK : Issues Voluntary Nationwide Recall of CUBICIN® (daptomycin for injection) 500 mg, ..
20/10Merck & Co., Inc. Issues Voluntary Nationwide Recall of CUBICIN? (daptomycin for inject..
19/10MERCK : WHO Program Aims to Secure COVID-19 Antiviral Drugs for Poorer Nations for $10 per..
19/10Health Care Stocks Adding to Tuesday Recovery in Late Trade
19/10Earnings season continues to deliver
15/10MERCK : And Co. Gets European Medicines Agency's Positive Opinions on Pneumonia Vaccine, C..
15/10MERCK : Receives Positive Opinions From European Medicines Agency on Pneumonia Vaccine, Ca..
15/10Merck, Eisai Get CHMP Backing for Lenvima-Keytruda Combo in Two Cancers
15/10Merck & Co erhält EU-Zulassungsemfehlung bei Krebsmittel
1  2  3  4  5  6  7  8  9  10Suiv.
Prochain événement sur MERCK & CO., INC.